“Billy is extremely well versed in protein expression and characterization as well as always interested in new technologies and processes to make his work more valuable, accurate and efficient. Although not directly under his supervision he displayed a personable and reliable management style that anyone would take something from. It was a pleasure working with him for four years and I will always value his advice and honesty.”
Über uns
Billie Key has over 25 years of experience in the pharmaceutical and academic research…
Activity
-
Today we announced an exciting new chapter in our story as pioneers of microbiome therapeutics: an agreement with long-time partner Nestlé Health…
Today we announced an exciting new chapter in our story as pioneers of microbiome therapeutics: an agreement with long-time partner Nestlé Health…
Liked by Bill Key
-
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes. To view the full press release, visit our website:…
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes. To view the full press release, visit our website:…
Liked by Bill Key
-
Seres is excited to present preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b…
Seres is excited to present preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b…
Liked by Bill Key
Erleben Sie
Bildung
Volunteer Experience
-
Soccer Coach-Various Ages & Teams
Conroe YMCA
- 9 years 1 month
Children
Teach children from PreK-7th grade the fundamentals of soccer, and help them to improve themselves in mind, spirit, and body!
Publications
-
Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma
Journal of Medicinal Chemistry
The discovery of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported. These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good selectivity against ROCK. After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels. The compounds also increase outflow facility in a pig eye perfusion assay. These results suggest LIMK2 may be an effective target for treating…
The discovery of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported. These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good selectivity against ROCK. After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels. The compounds also increase outflow facility in a pig eye perfusion assay. These results suggest LIMK2 may be an effective target for treating ocular hypertension and associated glaucoma.
Other authorsSee publication -
Glycosylphosphatidylinositol-anchored HDL-binding protein stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4
The Journal of Lipid Research
Glycosylphosphatidylinositol-anchored HDL-binding protein (GPIHBP1) binds both LPL and chylomicrons, suggesting that GPIHBP1 is a platform for LPL-dependent processing of triglyceride (TG)-rich lipoproteins. Here, we investigated whether GPIHBP1 affects LPL activity in the absence and presence of LPL inhibitors angiopoietin-like (ANGPTL)3 and ANGPTL4. Like heparin, GPIHBP1 stabilized but did not activate LPL. ANGPTL4 potently inhibited nonstabilized LPL as well as heparin-stabilized LPL but not…
Glycosylphosphatidylinositol-anchored HDL-binding protein (GPIHBP1) binds both LPL and chylomicrons, suggesting that GPIHBP1 is a platform for LPL-dependent processing of triglyceride (TG)-rich lipoproteins. Here, we investigated whether GPIHBP1 affects LPL activity in the absence and presence of LPL inhibitors angiopoietin-like (ANGPTL)3 and ANGPTL4. Like heparin, GPIHBP1 stabilized but did not activate LPL. ANGPTL4 potently inhibited nonstabilized LPL as well as heparin-stabilized LPL but not GPIHBP1-stabilized LPL. Like ANGPTL4, ANGPTL3 inhibited nonstabilized LPL but not GPIHBP1-stabilized LPL. ANGPTL3 also inhibited heparin-stabilized LPL but with less potency than nonstabilized LPL. Consistent with these in vitro findings, fasting serum TGs of Angptl4−/−/Gpihbp1−/− mice were lower than those of Gpihbp1−/− mice and approached those of wild-type littermates. In contrast, serum TGs of Angptl3−/−/Gpihbp1−/− mice were only slightly lower than those of Gpihbp1−/− mice. Treating Gpihbp1−/− mice with ANGPTL4- or ANGPTL3-neutralizing antibodies recapitulated the double knockout phenotypes. These data suggest that GPIHBP1 functions as an LPL stabilizer. Moreover, therapeutic agents that prevent LPL inhibition by ANGPTL4 or, to a lesser extent, ANGPTL3, may benefit individuals with hyperlipidemia caused by gene mutations associated with decreased LPL stability.
Other authorsSee publication -
Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice.
Proceedings of the National Academy of Sciences of the United States of America
We used gene knockout mice to explore the role of Angiopoietin-like-4 (Angptl4) in lipid metabolism as well as to generate anti-Angptl4 mAbs with pharmacological activity. Angptl4 −/− mice had lower triglyceride (TG) levels resulting both from increased very low-density lipoprotein (VLDL) clearance and decreased VLDL production and had modestly lower cholesterol levels. Also, both Angptl4 −/− suckling mice and adult mice fed a high-fat diet showed reduced viability associated with…
We used gene knockout mice to explore the role of Angiopoietin-like-4 (Angptl4) in lipid metabolism as well as to generate anti-Angptl4 mAbs with pharmacological activity. Angptl4 −/− mice had lower triglyceride (TG) levels resulting both from increased very low-density lipoprotein (VLDL) clearance and decreased VLDL production and had modestly lower cholesterol levels. Also, both Angptl4 −/− suckling mice and adult mice fed a high-fat diet showed reduced viability associated with lipogranulomatous lesions of the intestines and their draining lymphatics and mesenteric lymph nodes. Treating C57BL/6J, ApoE −/−, LDLr −/−, and db/db mice with the anti-Angptl4 mAb 14D12 recapitulated the lipid and histopathologic phenotypes noted in Angptl4 −/− mice. This demonstrates that the knockout phenotype reflects not only the physiologic function of the Angptl4 gene but also predicts the pharmacologic consequences of Angptl4 protein inhibition with a neutralizing antibody in relevant models of human disease.
Other authorsSee publication -
Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention.
Proceedings of the National Academy of Sciences of the United States of America
The availability of both the mouse and human genome sequences
allows for the systematic discovery of human gene function
through the use of the mouse as a model system. To accelerate the
genetic determination of gene function, we have developed a
sequence-tagged gene-trap library of >270,000 mouse embryonic
stem cell clones representing mutations in 60% of mammalian
genes. Through the generation and phenotypic analysis of knockout
mice from this resource, we are…The availability of both the mouse and human genome sequences
allows for the systematic discovery of human gene function
through the use of the mouse as a model system. To accelerate the
genetic determination of gene function, we have developed a
sequence-tagged gene-trap library of >270,000 mouse embryonic
stem cell clones representing mutations in 60% of mammalian
genes. Through the generation and phenotypic analysis of knockout
mice from this resource, we are undertaking a functional screen
to identify genes regulating physiological parameters such as
blood pressure. As part of this screen, mice deficient for the Wnk1
kinase gene were generated and analyzed. Genetic studies in
humans have shown that large intronic deletions in WNK1 lead to
its overexpression and are responsible for pseudohypoaldosteronism
type II, an autosomal dominant disorder characterized by
hypertension, increased renal salt reabsorption, and impaired K
and H excretion. Consistent with the human genetic studies,
Wnk1 heterozygous mice displayed a significant decrease in blood
pressure. Mice homozygous for the Wnk1 mutation died during
embryonic development before day 13 of gestation. These results
demonstrate that Wnk1 is a regulator of blood pressure critical for
development and illustrate the utility of a functional screen driven
by a sequence-based mutagenesis approach.Other authorsSee publication
Projects
-
Updating Import Manuals & Amending Export Procedures
-
Develop In-House Inventory Mgt System
Goal is to develop a system to track supply chain materials through the various steps/vendors and managed not only quantity, but expiry, and lot genealogy. Later modules will be able to interface with vendor systems as well as courier shipping systems to create a shipment tracking module. Finally the system will be able to track and manage key international trade metrics to ensure budgets are on track as well as aiding compliance.
Organizations
-
American Association of Exporters and Importers
-
- PresentJoined AAEI Healthcare Group
-
International Compliance Professionals Association
-
- PresentTake Part in the Quarterly ICPA Houston DATA Group
Recommendations received
2 people have recommended Bill
Join now to viewOther similar profiles
Gemeinsame Artikel erkunden
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Bill Key in United States
-
Bill Key
Recruiting Manager for Orion Talent
-
Bill Key
Physical Trading Mgr at NextEra Energy Power Marketing
-
Bill Key
Principal WK Techgroup LLC
-
Bill Key
124 others named Bill Key in United States are on LinkedIn
See others named Bill Key